• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model?

    Simply Wall St·07/22/2026 22:21:31
    语音播报
    • In July 2026, Halozyme Therapeutics announced a global collaboration and licence agreement with Incyte to apply its ENHANZE drug delivery technology to develop additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin in myeloproliferative neoplasms, with Halozyme eligible for upfront, milestone and royalty payments on future commercial products.
    • This partnership underlines how Halozyme can integrate its ENHANZE platform into precision oncology programs like INCA033989, potentially broadening royalty-bearing applications in blood cancers and adding to its portfolio of platform-based collaborations.
    • We’ll now examine how this new ENHANZE partnership with Incyte could influence Halozyme’s investment narrative built around expanding royalty streams.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

    Halozyme Therapeutics Investment Narrative Recap

    To own Halozyme, you need to believe in its ENHANZE platform as a durable, high‑margin royalty engine, supported by growing adoption of subcutaneous biologics and disciplined capital returns. The new Incyte deal adds another potential royalty source in blood cancers, but it does not obviously change the near term focus on partner launches and execution, nor does it lessen key risks around patent challenges, drug pricing pressure, and revenue concentration in a handful of blockbuster collaborations.

    The most relevant recent development alongside Incyte is the May 2026 global ENHANZE collaboration with GSK in oncology, which also adds multiple potential future royalty streams. Together, these partnerships show Halozyme continuing to broaden its partner base around ENHANZE, while investor attention still centers on how quickly existing launches ramp and how IP and pricing risks evolve relative to management’s upgraded 2026 revenue guidance of US$1,710 million to US$1,810 million.

    Yet beneath these new partnerships, a lesser discussed risk investors should be aware of is how ongoing patent challenges could eventually...

    Read the full narrative on Halozyme Therapeutics (it's free!)

    Halozyme Therapeutics' narrative projects $2.1 billion revenue and $1.1 billion earnings by 2029.

    Uncover how Halozyme Therapeutics' forecasts yield a $83.90 fair value, a 8% upside to its current price.

    Exploring Other Perspectives

    HALO 1-Year Stock Price Chart
    HALO 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming Halozyme could reach about US$2.3 billion in revenue and US$1.2 billion in earnings by 2029, and viewed long term patent exclusivity as the main swing factor. This new Incyte partnership may strengthen that bullish view or sharpen concerns about how much ENHANZE depends on strong IP protection, so it is worth comparing these more aggressive expectations with your own assumptions about sustainability of royalty growth and legal outcomes.

    Explore 5 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 4x more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Want Some Alternatives?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.